Olmos, D., Baird, R. D., Yap, T. A., Massard, C., Pope, L., Sandhu, S. K., Attard, G., Dukes, J., Papadatos-Pastos, D., Grainger, P., Kaye, S. B., de Bono, J. S. (2011) Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. CLINICAL CANCER RESEARCH, 17 (15). pp. 5188-5196. ISSN 1078-0432

Full text not available from this repository.

Abstract

Background: High circulating tumor cell (CTC) counts are associated with poor prognosis in several cancers. Enrollment of patients on phase I oncology trials requires a careful assessment of the potential risks and benefits. Many patients enrolled on such trials using established eligibility criteria have a short life expectancy and are less likely to benefit from trial participation. We hypothesized that the incorporation of CTC counts might improve patient selection for phase I trials. Methods: This retrospective analysis evaluated patients who had baseline CTCs enumerated prior to their starting on a phase I trial. CTCs were enumerated using the CellSearch System. Results: Between January 2006 and December 2009 a total of 128 patients enrolled in phase I trials had CTC counts evaluated. Higher CTC counts as a continuous variable independently correlated with risk of death in this patient population (P = 0.006). A multivariate point-based risk model was generated using CTCs as a dichotomous variable (>= 3 or < 3), and incorporated other established prognostic factors, including albumin < 35 g/L, lactate dehydrogenase greater than upper limit of normal, and > 2 metastatic sites. Comparison of receiver operating characteristic curves demonstrated that the addition of baseline CTC counts improved the performance of the prospectively validated Royal Marsden Hospital phase I prognostic score, which now identifies three risk groups (P < 0.0001): good prognosis [score 0-1, median overall survival (OS) 63.7 weeks], intermediate prognosis (score 2-3, median OS 37.3 weeks), and poor prognosis (score 4, median OS 13.4 weeks). Conclusion: CTC enumeration improved the performance of a validated prognostic score to help select patients for phase I oncology trials. Clin Cancer Res; 17(15); 5188-96. (C) 2011 AACR.

Item Type:	Article
Authors (ICR Faculty only):	De-Bono, Johann and Kaye, Stan
All Authors:	Olmos, D., Baird, R. D., Yap, T. A., Massard, C., Pope, L., Sandhu, S. K., Attard, G., Dukes, J., Papadatos-Pastos, D., Grainger, P., Kaye, S. B., de Bono, J. S.
Additional Information:	ISI Document Delivery No.: 800CH Times Cited: 0 Cited Reference Count: 37 Olmos, David Baird, Richard D. Yap, Timothy A. Massard, Christophe Pope, Lorna Sandhu, Shahneen K. Attard, Gerhardt Dukes, Juliet Papadatos-Pastos, Dionysis Grainger, Philippa Kaye, Stan B. de Bono, Johann S. Immunicom and Veridex for investigation on CTC in Prostate Cancer The research team lead by J.S. de Bono has received commercial research support from Immunicom and Veridex for investigation on CTC in Prostate Cancer. Amer assoc cancer research Philadelphia
Uncontrolled Keywords:	metastatic breast-cancer resistant prostate-cancer clinical-trials center experience predict survival progression-free benefits risks guidelines context
Research teams:	ICR divisions > Cancer Therapeutics > Medicine (Kaye Drug Development Unit) ICR divisions > Clinical Studies > Medicine (Kaye Drug Development Unit) ICR divisions > Cancer Therapeutics > Cancer Biomarkers ICR divisions > Clinical Studies > Cancer Biomarkers ICR divisions > Clinical Studies > Prostate Cancer Targeted Therapy Group
Depositing User:	Alexander Smithson
Date Deposited:	15 Aug 2011 15:40
Last Modified:	11 Jul 2017 13:42
URI:	http://publications.icr.ac.uk/id/eprint/10930

Actions (login required)

View Item